April 2019

positive opinion for ravulizumab

Ravulizumab (Ultomiris®), the successor to eculizumab (Soliris®) by the manufacturer Alexion Pharmaceuticals, Inc., has been approved by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines AgencyWEITER
Loading new posts...
No more posts